Danmark - dansk - SEGES Landbrug & Fødevarer

verdera oy - clonostachys - vanddispergerbart pulver - 100000000000 cfu/kg clonostachys rosea stamme j1446 (=gliocladium catenulatum stamme j1446)

Danmark - dansk - SEGES Landbrug & Fødevarer

verdera oy - phlebiopsis - suspensionskoncentrat - 2000000000 cfu/kg phlebiopsis gigantea stamme vra 1835

Danmark - dansk - SEGES Landbrug & Fødevarer

verdera oy - clonostachys - vanddispergerbart pulver - 100000000000 cfu/kg clonostachys rosea stamme j1446 (=gliocladium catenulatum stamme j1446)

Danmark - dansk - SEGES Landbrug & Fødevarer

verdera oy - clonostachys - vanddispergerbart pulver - 100000000000 cfu/kg clonostachys rosea stamme j1446 (=gliocladium catenulatum stamme j1446)

Danmark - dansk - SEGES Landbrug & Fødevarer

verdera oy - streptomyces - vanddispergerbart pulver - 500000000000 cfu/kg streptomyces k61

Danmark - dansk - SEGES Landbrug & Fødevarer

verdera oy - phlebiopsis - vanddispergerbart pulver - 2000000000 cfu/kg phlebiopsis gigantea stamme vra 1835

Danmark - dansk - SEGES Landbrug & Fødevarer

verdera oy - streptomyces - vanddispergerbart pulver - 500000000000 cfu/kg streptomyces k61

Danmark - dansk - SEGES Landbrug & Fødevarer

danstar ferment ag - phlebiopsis - suspensionskoncentrat - 2000000000 cfu/kg phlebiopsis gigantea stamme vra 1835

Den Europæiske Union - dansk - EMA (European Medicines Agency)

actavis group ptc ehf    - pioglitazonhydrochlorid - diabetes mellitus, type 2 - narkotika anvendt i diabetes - pioglitazone is indicated as second or third line treatment of type-2 diabetes mellitus as described below:as monotherapy:in adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance;as dual oral therapy in combination with:metformin, in adult patients (particularly overweight patients) with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin;a sulphonylurea, only in adult patients who show intolerance to metformin or for whom metformin is contraindicated, with insufficient glycaemic control despite maximal tolerated dose of monotherapy with a sulphonylurea;as triple oral therapy in combination with:metformin and a sulphonylurea, in adult patients (particularly overweight patients) with insufficient glycaemic control despite dual oral therapy. pioglitazone er også indiceret til kombination med insulin ved type 2-diabetes mellitus voksne patienter med utilstrækkelig glykæmisk kontrol på insulin, for hvem metformin er uegnet på grund af kontraindikationer eller intolerance. efter initiering af behandling med pioglitazon, patienter bør revurderes efter 3 til 6 måneder for at vurdere tilstrækkeligheden af respons på behandlingen (e. reduktion i hba1c). hos patienter, der undlader at vise et passende svar, pioglitazon bør seponeres. i lyset af potentielle risici med langvarig terapi, ordinerende læger bør bekræftes ved en efterfølgende rutinemæssige vurderinger, der har gavn af pioglitazon er fastholdt.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

actavis group ptc ehf   - pioglitazonhydrochlorid - diabetes mellitus, type 2 - narkotika anvendt i diabetes - pioglitazone is indicated as second or third line treatment of type 2 diabetes mellitus as described below:as monotherapyin adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance. as dual oral therapy in combination withmetformin, in adult patients (particularly overweight patients) with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin. a sulphonylurea, only in adult patients who show intolerance to metformin or for whom metformin is contraindicated, with insufficient glycaemic control despite maximal tolerated dose of monotherapy with a sulphonylurea. as triple oral therapy in combination withmetformin and a sulphonylurea, in adult patients (particularly overweight patients) with insufficient glycaemic control despite dual oral therapy. pioglitazone is also indicated for combination with insulin in type 2 diabetes mellitus adult patients with insufficient glycaemic control on insulin for whom metformin is inappropriate because of contraindications or intolerance (see section 4. efter initiering af behandling med pioglitazon, patienter bør revurderes efter 3 til 6 måneder for at vurdere tilstrækkeligheden af respons på behandlingen (e. reduktion i hba1c). hos patienter, der undlader at vise et passende svar, pioglitazon bør seponeres. i lyset af potentielle risici med langvarig terapi, ordinerende læger bør bekræftes ved en efterfølgende rutinemæssige vurderinger, der har gavn af pioglitazon er fastholdt (se afsnit 4.